Join us in Houston for the 2024 DTRF Together We Will Weekend and RFA Walk. - Register Today!

The Desmoid Tumor Research Foundation

January 2021

Ultrasound-guided Vacuum-assisted Biopsy Versus Surgical Resection in Patients With Breast Desmoid Tumor

Author Information

Mei J(1), Hu (1), Jiang X(1), Zhong W(1), Tan C(2), Gu R(1), Liu F(1), Yang Y(1), Wang H(1), Shen S(1), Gong C(3).

(1)Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics & Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univ, Guangdong, China; Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univ, Guangdong, China. (2)Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics & Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univ, Guangdong, China; Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univ, Guangdong, China. (3)Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics & Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univ, Guangdong, China; Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univ, Guangdong, China; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.

Publication

J Surg Res

Summary

Recent studies suggest that desmoid tumors can be managed more conservatively rather than undergoing wide surgical resection (SR). Ultrasound-guided vacuum-assisted biopsy (UGVAB) is a minimally invasive technique. This retrospective study aimed to compare the outcome in patients with breast desmoid tumor (BDT) who received UGVAB alone versus SR. The pathology database was searched for patients diagnosed with BDT ? 3 cm from 2007 to 2019. All patients underwent breast ultrasound examination and were then performed UGVAB alone or local SR. A total of 39 patients were included. The median follow-up was 41 mo (range, 5-110 mo). The incidence of tumor recurrence was 23.1% (9/39). The 3-y cumulative RFS was 83.1% and 95.8% in the UGVAB and SR group, respectively, which was not significantly different between the two groups (P = 0.131, log-rank test). Multivariate analysis also revealed that treatment strategy (UGVAB versus SR) was not associated with an increased risk of relapse events (P = 0.274). Small desmoid tumors (?3 cm) after UGVAB alone did not have a significantly compromised RFS compared with those who underwent SR. UGVAB may be an alternative and relatively conservative method for the diagnosis and local control of BDT with a smaller size. A prospective, randomized study with large sample size is needed to confirm this observation.

View Abstract